-+ 0.00%
-+ 0.00%
-+ 0.00%

Regeneron Pharmaceuticals Says EC Approves Alternative, Flexible Dosing Schedule For Libtayo Across All Approved Skin, Lung And Cervical Cancer Indications

Benzinga·11/17/2026 12:06:24
Listen to the news

Approval introduces an extended dosing regimen of Libtayo 700 mg given every six weeks, following initial 12 weeks of treatment with Libtayo 350 mg every three weeks

Also approved is an option of reducing subsequent infusion times of Libtayo 350 mg by up to half, from 30 minutes to 15 minutes, after a well-tolerated 30-minute infusion

TARRYTOWN, N.Y., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the European Commission (EC) has approved an alternative, flexible dosing schedule for Libtayo® (cemiplimab) across all approved skin, lung and cervical cancer indications. The EC approval provides patients with the option to receive a higher, 700 mg dose of Libtayo every six weeks infused intravenously over 30 minutes, after completing initial 12 weeks of treatment with Libtayo 350 mg infused intravenously over 30 minutes every three weeks. Additionally, the approval allows those whose first 30-minute infusion of Libtayo 350 mg was well tolerated to reduce their subsequent infusion times to 15- to 30-minutes at this dose level.